CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Amgen
Lyell Immunopharma, Inc.
BeOne Medicines
Immatics US, Inc.
Beijing Biotech
Gilead Sciences
Autolus Limited
Bristol-Myers Squibb
ModernaTX, Inc.
Hoffmann-La Roche
ModernaTX, Inc.
AstraZeneca
Nanjing IASO Biotechnology Co., Ltd.
Regeneron Pharmaceuticals
Daiichi Sankyo
Servier
Amgen
Beijing Biotech
Pfizer
AstraZeneca
Hoffmann-La Roche
Sumitomo Pharma America, Inc.
Celgene
Curis, Inc.
Beijing Biotech
Beijing Biotech
Janssen Research & Development, LLC
Sellas Life Sciences Group
Allogene Therapeutics
Otsuka Pharmaceutical Co., Ltd.
A2 Biotherapeutics Inc.
Celgene
Celgene
SymBio Pharmaceuticals
BIOHENG THERAPEUTICS US LLC
Incyte Corporation
Haihe Biopharma Co., Ltd.
DualityBio Inc.
GlaxoSmithKline
Blueprint Medicines Corporation
Kura Oncology, Inc.
Karyopharm Therapeutics Inc
Genmab
MediLink Therapeutics (Suzhou) Co., Ltd.
Seqker Biosciences, Inc.
Novelwise Pharmaceutical Corporation
Regeneron Pharmaceuticals
Immatics Biotechnologies GmbH
Incyte Corporation